DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

Retatrutide phase 2 trial results

Adults with obesity or overweight with a related condition, without diabetes.

Retatrutide
Phase
Phase 2
Follow-up
24 weeks
Randomised
338
Sponsor
Eli Lilly
Publication
New England Journal of Medicine · 2023

Randomised, double-blind, placebo-controlled. Efficacy estimand.

Mean body weight change at 24 weeks
  • Retatrutide 1 mg−7.2%
  • Retatrutide 4 mg (pooled)−12.9%
  • Retatrutide 8 mg (pooled)−17.3%
  • Retatrutide 12 mg−17.5%
  • Placebo−1.6%
Mean body weight change at 24 weeks
Trial armResult
Retatrutide 1 mg−7.2%
Retatrutide 4 mg (pooled)−12.9%
Retatrutide 8 mg (pooled)−17.3%
Retatrutide 12 mg−17.5%
Placebo−1.6%

Safety. Gastrointestinal events were most common and generally mild to moderate.

Published paper PubMed abstract NCT04881760